Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

917 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR, Vasilakos JP, Deschler K, Grigsby I, Gillis P, John J, Elder MJ, Swales J, Timosenko E, Cooper Z, Dovedi SJ, Leishman AJ, Luheshi N, Elvecrog J, Tilahun A, Goodwin R, Herbst R, Tomai MA, Wilkinson RW. Mullins SR, et al. Among authors: herbst r. J Immunother Cancer. 2019 Sep 11;7(1):244. doi: 10.1186/s40425-019-0724-8. J Immunother Cancer. 2019. PMID: 31511088 Free PMC article.
Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment.
Hewitt SL, Bailey D, Zielinski J, Apte A, Musenge F, Karp R, Burke S, Garcon F, Mishra A, Gurumurthy S, Watkins A, Arnold K, Moynihan J, Clancy-Thompson E, Mulgrew K, Adjei G, Deschler K, Potz D, Moody G, Leinster DA, Novick S, Sulikowski M, Bagnall C, Martin P, Lapointe JM, Si H, Morehouse C, Sedic M, Wilkinson RW, Herbst R, Frederick JP, Luheshi N. Hewitt SL, et al. Among authors: herbst r. Clin Cancer Res. 2020 Dec 1;26(23):6284-6298. doi: 10.1158/1078-0432.CCR-20-0472. Epub 2020 Aug 17. Clin Cancer Res. 2020. PMID: 32817076
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E. André P, et al. Among authors: herbst r. Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. Cell. 2018. PMID: 30503213 Free PMC article. Review.
Targeting CD73 in the tumor microenvironment with MEDI9447.
Hay CM, Sult E, Huang Q, Mulgrew K, Fuhrmann SR, McGlinchey KA, Hammond SA, Rothstein R, Rios-Doria J, Poon E, Holoweckyj N, Durham NM, Leow CC, Diedrich G, Damschroder M, Herbst R, Hollingsworth RE, Sachsenmeier KF. Hay CM, et al. Among authors: herbst r. Oncoimmunology. 2016 Jul 11;5(8):e1208875. doi: 10.1080/2162402X.2016.1208875. eCollection 2016 Aug. Oncoimmunology. 2016. PMID: 27622077 Free PMC article.
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Durham NM, Mulgrew K, McGlinchey K, Monks NR, Ji H, Herbst R, Suzich J, Hammond SA, Kelly EJ. Durham NM, et al. Among authors: herbst r. Mol Ther. 2017 Aug 2;25(8):1917-1932. doi: 10.1016/j.ymthe.2017.05.006. Epub 2017 Jun 2. Mol Ther. 2017. PMID: 28578991 Free PMC article.
A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z, Carrasco RA, Schifferli K, Kinneer K, Tammali R, Chen H, Rothstein R, Wetzel L, Yang C, Chowdhury P, Tsui P, Steiner P, Jallal B, Herbst R, Hollingsworth RE, Tice DA. Xiao Z, et al. Among authors: herbst r. Mol Cancer Ther. 2016 Apr;15(4):689-701. doi: 10.1158/1535-7163.MCT-15-0555. Epub 2016 Feb 15. Mol Cancer Ther. 2016. PMID: 26880266
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Lin H, et al. Among authors: herbst r. J Clin Invest. 2018 Feb 1;128(2):805-815. doi: 10.1172/JCI96113. Epub 2018 Jan 16. J Clin Invest. 2018. PMID: 29337305 Free PMC article.
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.
Pore N, Wu S, Standifer N, Jure-Kunkel M, de Los Reyes M, Shrestha Y, Halpin R, Rothstein R, Mulgrew K, Blackmore S, Martin P, Meekin J 3rd, Griffin M, Bisha I, Proia TA, Miragaia RJ, Herbst R, Gupta A, Abdullah SE, Raja R, Frigault MM, Barrett JC, Dennis PA, Ascierto ML, Oberst MD. Pore N, et al. Among authors: herbst r. Cancer Discov. 2021 Nov;11(11):2828-2845. doi: 10.1158/2159-8290.CD-20-1543. Epub 2021 Jul 6. Cancer Discov. 2021. PMID: 34230008
The Immunoscore: Colon Cancer and Beyond.
Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. Angell HK, et al. Among authors: herbst r. Clin Cancer Res. 2020 Jan 15;26(2):332-339. doi: 10.1158/1078-0432.CCR-18-1851. Epub 2019 Aug 14. Clin Cancer Res. 2020. PMID: 31413009 Review.
917 results